Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
Correale P, Saladino RE, Nardone V, Giannicola R, Agostino R, Pirtoli L, Caraglia M, Botta C, Tagliaferri P. Correale P, et al. Among authors: giannicola r. Immunotherapy. 2019 Dec;11(18):1523-1526. doi: 10.2217/imt-2019-0160. Epub 2019 Dec 9. Immunotherapy. 2019. PMID: 31865873 No abstract available.
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.
Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P. Correale P, et al. Among authors: giannicola r. Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755670 Free PMC article.
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.
Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P. Giannicola R, et al. Mol Clin Oncol. 2019 Jul;11(1):81-90. doi: 10.3892/mco.2019.1859. Epub 2019 May 16. Mol Clin Oncol. 2019. PMID: 31289683 Free PMC article.
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.
Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P. Caraglia M, et al. Among authors: giannicola r. Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019. Front Oncol. 2019. PMID: 31781481 Free PMC article.
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.
Nardone V, Tini P, Pastina P, Botta C, Reginelli A, Carbone SF, Giannicola R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale P. Nardone V, et al. Among authors: giannicola r. Oncol Lett. 2020 Feb;19(2):1559-1566. doi: 10.3892/ol.2019.11220. Epub 2019 Dec 16. Oncol Lett. 2020. PMID: 31966081 Free PMC article.
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Correale P, Saladino RE, Giannarelli D, Giannicola R, Agostino R, Staropoli N, Strangio A, Del Giudice T, Nardone V, Altomonte M, Pastina P, Tini P, Falzea AC, Imbesi N, Arcati V, Romeo G, Caracciolo D, Luce A, Caraglia M, Giordano A, Pirtoli L, Necas A, Amler E, Barbieri V, Tassone P, Tagliaferri P. Correale P, et al. Among authors: giannicola r. J Immunother Cancer. 2020 Jun;8(1):e000733. doi: 10.1136/jitc-2020-000733. J Immunother Cancer. 2020. PMID: 32554614 Free PMC article.
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
Correale P, Saladino RE, Giannarelli D, Sergi A, Mazzei MA, Bianco G, Giannicola R, Iuliano E, Forte IM, Calandruccio ND, Falzea AC, Strangio A, Nardone V, Pastina P, Tini P, Luce A, Caraglia M, Caracciolo D, Mutti L, Tassone P, Pirtoli L, Giordano A, Tagliaferri P. Correale P, et al. Among authors: giannicola r. Cells. 2020 Aug 25;9(9):1964. doi: 10.3390/cells9091964. Cells. 2020. PMID: 32854442 Free PMC article.
On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer.
Correale P, Giannicola R, Saladino RE, Nardone V, Pirtoli L, Tassone P, Luce A, Cappabianca S, Scrima M, Tagliaferri P, Caraglia M. Correale P, et al. Among authors: giannicola r. Transl Lung Cancer Res. 2020 Oct;9(5):1712-1719. doi: 10.21037/tlcr-20-536. Transl Lung Cancer Res. 2020. PMID: 33209592 Free PMC article. No abstract available.
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade.
Nardone V, Giannicola R, Bianco G, Giannarelli D, Tini P, Pastina P, Falzea AC, Macheda S, Caraglia M, Luce A, Zappavigna S, Mutti L, Pirtoli L, Giordano A, Correale P. Nardone V, et al. Among authors: giannicola r. Front Oncol. 2021 Jun 14;11:684110. doi: 10.3389/fonc.2021.684110. eCollection 2021. Front Oncol. 2021. PMID: 34195086 Free PMC article.
22 results